Genetics, artificial intelligence, new treatment protocols — pharmacology took a step in April from which there will be no turning back.
NeurogeneRx has entered clinical trials for a drug that adapts to a patient’s genetic profile in real time. It’s not magic, but a CRISPR-integrated nano-delivery formula.
No longer a “one pill fits all” — but a spot treatment that reads you better than a doctor.
The Ministry of Health has certified the CalmDose mobile app as a form of therapy for anxiety disorders. It is a program built on cognitive behavioral therapy that has pharmacological status.
What this means: now you can be “prescribed” not a pill, but an app that works with the patient’s neurobehavior.
In April, DeepMedLabs reported successfully formulating an anti-cancer drug in 5 months, instead of the usual 12-18. This was possible thanks to the use of a GPT-based model that calculates molecular interactions in minutes.
Trigger for investors: Medicine is entering an era where time is the new currency. Whoever shortens the cycle first will win.
The April resolution of the European Medical Agency was historic: microdoses of psilocybin are recommended for use as part of supervised therapy.
A trigger for the community: what was “psychonautics” yesterday is now a treatment supported by science.
The world has long lived in fear of superbugs that are immune to classic antibiotics. In April, a study published in The Lancet described a new molecule, PLX-0891, that can penetrate even the most resistant strains.
What this means: a weapon that can save millions has reappeared in the pharmaceutical world.
Pharmacology is no longer just about chemistry. It is a synthesis of data, bioengineering, psychology, and technology that together create a new model of health.
And if you still see medicine only as a “pill” — take a broader view: sometimes real treatment begins not in the pharmacy, but in the code.
Technical analysis of depolarization (TDP) in an ERVO stack. Economics of organic waste processing and EROEI indicators. Expert assessment by Oleksandr Mospanenko.
Resistance analysis of ESKAPE strains.. Methodology by A. Demchenko for C-level Pharma.
Scientific justification for the reclamation of technozems. Bioremediation based on glauconite according to patents of the AVELIFE Institute. Expert assessment by Timur Levda for agricultural holdings
